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Abstract: These studies investigated the absorption and metabolic conversion of lisdexamfe-
tamine dimesylate (LDX), a prodrug stimulant that requires conversion to d-amphetamine for 
activity. Oral absorption of LDX was assessed in rat portal and jugular blood, and perfusion of 
LDX into isolated intestinal segments of anesthetized rats was used to assess regional absorption. 
Carrier-mediated transport of LDX was investigated in Caco-2 cells and Chinese hamster ovary 
(CHO) cells expressing human peptide transporter-1 (PEPT1). LDX metabolism was studied in 
rat and human tissue homogenates and human blood fractions. LDX was approximately10-fold 
higher in portal blood versus systemic blood. LDX and d-amphetamine were detected in blood 
following perfusion of the rat small intestine but not the colon. Transport of LDX in Caco-2 
cells had permeability apparently similar to cephalexin and was reduced with concurrent PEPT1 
inhibitor. Affinity for PEPT1 was also demonstrated in PEPT1-transfected CHO cells. LDX 
metabolism occurred primarily in whole blood (rat and human), only with red blood cells. 
Slow hydrolysis in liver and kidney homogenates was probably due to residual blood. The 
carrier-mediated absorption of intact LDX, likely by the high-capacity PEPT1 transporter, and 
subsequent metabolism to d-amphetamine in a high-capacity system in blood (ie, red blood 
cells) may contribute to the consistent, reproducible pharmacokinetic profile of LDX.
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Introduction
Lisdexamfetamine dimesylate (LDX; Vyvanse, Shire US Inc.) is the first long-acting 
prodrug stimulant indicated for the treatment of attention-deficit/hyperactivity disorder 
(ADHD) in children aged six to 12 years and in adults. After oral administration, LDX 
is converted to l-lysine and d-amphetamine, the latter being the active drug for the 
treatment of ADHD (Figure 1).
LDX has been shown to provide a long duration of effect, which allows once-daily 
dosing.1 Low interpatient variability of d-amphetamine plasma levels from LDX has 
been suggested by consistent delivery of d-amphetamine from patient to patient in a 
study in children with ADHD and, similarly, within and between subjects in a clinical 
trial in healthy adults.2,3 Physicochemical and biologic characteristics of LDX, such 
as high water solubility, lack of effect on absorption/conversion by changes in gastric 
  environment and pH, and gradual conversion of LDX to active d-amphetamine, may 
impact interpatient and intrapatient variability and consistent delivery of d-amphetamine 
from patient to patient in these studies.
LDX is the only prodrug available for treatment of ADHD. It is important to 
  understand the absorption and enzymatic conversion of intact LDX to the active 
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  moiety, d-amphetamine. The aim of the following studies 
was to investigate the absorption and enzymatic conversion 
of LDX in rat and human tissue and cell culture models.
Methods and materials
Male Sprague–Dawley rats weighing approximately 240 
to 400 g (Hilltop Lab Animals Inc., Scottdale, PA) were 
  acclimated for at least two days. The rats were maintained on 
a 12-hour, light–dark cycle, had free access to water, and were 
fasted overnight before the experiment. For studies conducted 
in conscious rats, food was returned four hours postdose and 
the rats had free access to water and food throughout the 
study. All protocols involving animal experimentation were 
reviewed and approved by the Institution Animal Care and 
Use Committee of each test facility. In vivo procedures were in 
compliance with the National Research Council’s Guide for the 
Care and Use of Laboratory Animals.4 All protocols involving 
the use of human tissues were reviewed and approved by the 
Institutional Review Board for Human Research of each test 
facility. Unless otherwise noted, all chemicals were obtained 
from Sigma-Aldrich Corporation (St. Louis, MO). LDX was 
supplied by Shire (Basingstoke, Hampshire, UK).
Studies of LDX absorption
Oral absorption of LDX in conscious rats
Conscious rats with indwelling cannulae implanted in the 
jugular and portal veins were administered a single oral dose 
of LDX by gavage (10 mg/kg of LDX in 5 mL/kg of water). 
Whole blood was collected with concurrent replacement with 
donor blood from the portal and jugular veins at predose, 
10 and 30 minutes, and 1, 2, 4, 6, 8, and 24 hours postdose 
into tubes (4°C) containing potassium ethylenediamine 
tetra-acetic acid (EDTA) as an anticoagulant and centrifuged, 
and plasma was stored at −20°C prior to analysis.
Single-pass intestinal perfusion in anesthetized rats
Single-pass intestinal perfusion studies were performed in 
rats using modifications to established methods.5,6 Briefly, 
fasted male rats (n = 4 per group) were anesthetized with 
ketamine/xylazine (1 mL/kg) and placed on a heating pad 
to maintain body temperature. Intestinal segments were 
exposed by midline incision and externalized. The proxi-
mal ends of intestinal segments were identified as follows: 
1 to 2 cm below the pylorus for the duodenum, 10 cm below 
the pylorus for the jejunum, 15 cm above the ileocecal junc-
tion for the ileum, and 1 to 2 cm below the colocecal junction 
for the colon. A silicone cannula was placed at the proximal 
ends of each segment, and a small incision was made 10 cm 
below the proximal cannula. After flushing with warm saline, 
an intestinal loop was created by cannulation of the distal 
end of the segment. The lumens of the isolated segments 
were perfused (0.2 mL/min with a peristaltic pump) with an 
appropriate perfusion solution (Krebs-Ringer bicarbonate 
buffer at pH 6.5 for the duodenum and jejunum; pH 7.4 for 
the ileum and colon) at 37°C.
Experimental perfusions included three reference 
  compounds: fluorescein isothiocyanate-dextran (25 µM FD-4; 
average molecular mass = 4000 u), an unabsorbed marker; 
atenolol (100 µM), a low permeability marker; and antipyrine 
(100 µM), a high permeability marker. Perfusion was initiated 
with the test solution (LDX 0.125 mg/mL in perfusion solution 
with markers). Samples of perfusate (3 mL) were collected every 
15 minutes for 90 minutes postequilibration with simultaneous 
collection of blood samples from the femoral vein. Plasma was 
collected after centrifugation and stored at −20°C.
Permeability of LDX in Caco-2 cells
Caco-2 cell monolayers were grown to confluence on 
  collagen-coated, microporous, polycarbonate membranes 
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Figure 1 Enzymatic conversion of LDX to active d-amphetamine.
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in 12-well culture plates7 to establish an intact transporting 
  epithelial layer. The techniques have been previously reported 
and were adapted with minor modifications. The apical 
  permeability assay buffer (pH 6.0) was Hanks, balanced 
salt solution (HBSS) containing 10 mM 4 2-(N-morpholino) 
  ethanesulfonic acid and 15 mM glucose. The basolat-
eral assay buffer (pH 7.4) was HBSS containing 10 mM 
N-2-hydroxyethylpiperazine-n-2-ethanesulfonic acid and 
15 mM glucose. Cell monolayers were preincubated with 
appropriate assay buffer at 37°C for 30 minutes to establish 
a proton gradient. An additional set of monolayers was 
  preincubated with 5 mM glycylsarcosine (Gly-Sar), a known 
substrate of the peptide transporter-1 (PEPT1) transporter,7 in 
both chambers for 30 minutes to inhibit PEPT1 activity.
Transport experiments were initiated by the addition of 
10 µM LDX or 10 µM cephalexin, a reference substrate for 
the PEPT1 transporter,8 in assay buffer (pH 6.0) to the apical 
chambers, and assay buffer (pH 7.4) without agents was added 
to the basolateral chambers. For inhibition experiments, 5 mM 
Gly-Sar was also present in both chambers. Incubations were 
carried out at 37°C with 5% carbon dioxide in a humidified 
chamber. At one and two hours, 200 µL samples were taken 
from the basolateral chambers, and fresh assay buffer was 
added. Prior to the first incubation and at two hours, 100 µL 
of the apical assay buffer was collected. Each determination 
was performed in triplicate.
Further experiments assessed the permeability of LDX 
in Caco-2 cells that had been induced to overexpress the 
PEPT1 transporter. For these studies, 10 mM Gly-Sar 
was added to culture media, with daily replacement of the 
medium to induce expression of the PEPT1 transporter prior 
to experiments. Expression levels of PEPT1 were confirmed 
by quantitative polymerase chain reaction (qPCR)9 from total 
RNA isolated from Caco-2 cells and reverse-transcribed into 
cDNA. The qPCR was performed with predesigned sense 
and antisense primers of human PEPT1 and human β-actin 
as a housekeeping gene. Probes were fluorescein-labeled 
for fluorescent detection of PCR products. Reactions 
and detection of PCR products were carried out in the 
  LightCycler® 480 System (Roche, Nutley, NJ).
Inhibition of Gly-Sar transport by LDX in CHO cells
The potential for LDX to modify the uptake of the reporter 
substrate, Gly-Sar, into Chinese hamster ovary (CHO) 
cells expressing PEPT transporters was measured using a 
  modification of a previously described method.10 PEPT1-CHO, 
PEPT2-CHO, and CHO parent cells (100,000 cells/well) 
were grown for 24 hours in media supplemented with 5 mM 
sodium butyrate. Before the experiments, the medium was 
removed and cells were rinsed with Krebs–Henseleit buffer. 
Uptake experiments were carried out over 10 minutes at 37°C 
in 50 µL of Krebs–Henseleit buffer containing radiolabeled 
reporter substrate, Gly-Sar (2 µM) with or without LDX or 
vehicle, using previously described methods. LDX (10 to 
10,000 µM) or vehicle (dimethylsulfoxide [DMSO]) was 
added to duplicate wells. DMSO concentration did not exceed 
1% (vol/vol) in any assays. The reference inhibitors for 
PEPT1 (tyrosine-phenylalanine) and for PEPT2 (cefadroxil), 
both at 200 µM, were also assayed in duplicate as a positive 
control for Gly-Sar uptake inhibition. The amount of reporter 
substrate taken up by cultured cells was determined by liquid 
scintillation spectrometry. Uptake activity was reported 
as % activity: % activity = (A−B)/(C−D) × 100, where A is 
the amount of reporter substrate in the presence of LDX on 
transfected cells, B is the amount of reporter substrate in the 
presence of LDX on parent cells, C is the amount of reporter 
substrate in the presence of DMSO on transfected cells, and D 
is the amount of reporter substrate in the presence of DMSO 
on parent cells. Inhibitory activity of LDX was calculated as 
IC50 (µM) and efficacy (%) parameters. IC50 (µM) is defined 
as the concentration of LDX needed to inhibit maximal 
uptake of reporter substrate by 50%. Efficacy is defined as 
maximum inhibition achieved by LDX in percent maximal 
activity. GraphPad Prism 4.03 (GraphPad Software, Inc., 
La Jolla, CA) was used for curve fitting and determination 
of reaction parameters.
Studies of LDX hydrolysis
LDX hydrolysis in tissues and blood fractions  
from rats and human donors
Whole blood, plasma, liver, kidney, upper and lower small 
intestine, pancreas, and colon tissue samples were collected 
from three rats and two male human donors (surgical 
  remnant/death from a human tissue procurement center in 
  Philadelphia, PA). Amphetamine abusers were excluded. 
  Tissue samples from rats and human donors were homog-
enized in 0.1 M phosphate buffer. Because of intersubject 
variability in the human colon results, colon tissue samples 
were collected from an additional (third) human donor.
Human blood fractions, including red blood cells 
(RBCs), peripheral blood mononucleated cells (PBMCs), 
  polymorphonuclear cells (PMNs), and platelets, were 
  collected from two male donors and reconstituted in HBSS 
to concentrations equivalent to whole blood. Human RBC 
fractions from fresh blood collected from one male and one 
female donor were purchased from a commercial human Neuropsychiatric Disease and Treatment 2010:6 320
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blood cell supplier (Bioreclamation, Inc., New York, NY). 
Blood from donors with hematocrit outside the normal range 
were excluded.
Tissue or blood cell samples were incubated at 37°C in 
HBSS. Incubation reactions were initiated by the addition of 
LDX (1.0 µg/mL), and samples were collected for assay of 
LDX and d-amphetamine at 0, 0.25, 0.5, 1, 2, and 4 hours. 
Additionally, assay conditions included RBC fractions from 
each donor reconstituted with saline to 10%, 25%, 33%, 50%, 
75%, and 90% of the original hematocrit; one RBC fraction 
from each donor at 90% hematocrit lysed prior to incubation; 
and one RBC fraction at 100% hematocrit in the presence 
of additional EDTA (approximately 12.15 mg of potassium 
EDTA/7.0 mL of blood).
LDX stability in incubations with human liver 
microsome and rat and human hepatocytes
Human liver microsomes prepared from 15 individuals (male 
and female) and hepatocytes from rat and human livers 
  prepared according to previously published collagenase 
  perfusion methods11 were incubated with LDX. Human 
liver tissue for preparation of hepatocytes was obtained from 
rejected-for-transplant livers and discarded surgical remnants 
with appropriate consent from research tissue organizations 
and participating medical centers. Liver microsomes were 
  incubated with LDX (12.5 or 125 ng/mL) at 37°C for 
30 minutes. Hepatocyte suspensions (2 × 106 cells/mL), 
  prepared in Dulbecco’s modified Eagle’s medium with 
5% fetal bovine serum, were incubated with LDX (12.5 or 
125 ng/mL) at 37°C with samples collected at 0, 1, 2, and 
4 hours.
LDX stability in incubations with various peptidases
The stability of LDX was studied in the presence of three 
hydrolytic peptidase enzymes: human dipeptidyl peptidase IV , 
cathepsin G, and elastase. Buffer (pH 7.5) containing 25 mM 
of Tris HCl, 0.130 M of NaCl, and 0.0027 M of KCl was 
used for incubations with dipeptidyl peptidase IV and 
  elastase and 100 mM HEPES buffer (pH 7.5) for cathepsin 
G. Enzymes were dissolved in their respective buffer system 
(approximately 0.25 units/mL of dipeptidyl peptidase IV 
or 1.0 unit/mL of cathepsin G and elastase). Incubations at 
37°C with LDX (1 µg/mL) were for 0, 5, 15, 30, 45, and 
60 minutes.
The stability of LDX was studied in the presence of 
  simulated gastric fluid (SGF), simulated intestinal fluid 
(SIF), and trypsin. LDX (200 µg/mL) was incubated at 
37°C with either SGF containing porcine pepsin (pH ∼1.2) 
or SIF, containing porcine pancreatin (pH ∼6.8) (United 
States Pharmacopeia-National Formulary, 2005; United 
States Pharmacopeial Convention, Rockville, MD). Briefly, 
  incubations were at 37°C for 0, 5, 15, 30, 45, and 60 minutes. 
For incubation with trypsin, LDX (1 µg/mL) was incubated 
at 37°C in a 0.1 M potassium phosphate buffer (pH 7.4) with 
trypsin at concentrations of 100, 2000, or 20,000 units/mL. 
All in vitro reactions were terminated by the addition of 
0.5 mL of chilled acetonitrile.
Analytical methods
All samples were extracted by protein precipitation with 
acetonitrile and analyzed for LDX and d-amphetamine 
using an electrospray tandem liquid chromatography-mass 
  spectrometry (LC-MS/MS) method. Perfusate samples 
were also analyzed for the unabsorbed marker, FD-4, using 
a 96-well plate fluorescence plate reader (FLUOstar, BMG 
Labtech Inc., Durham, NC) with excitation and emission 
wavelengths of 492 and 520 nm. Perfusate and plasma 
samples were also analyzed for atenolol and antipyrine by 
LC-MS/MS.
Results
Studies of LDX absorption
Oral absorption of LDX in conscious rats
Figure 2 illustrates the plasma concentration-versus-time 
curves for systemic and portal circulation of LDX and 
d-amphetamine administered orally to rats. Pharmacokinetic 
studies in portal and jugular vein-cannulated rats showed 
that after administration of a single oral dose of LDX, 
intact LDX was rapidly absorbed from the gastrointestinal 
(GI) tract (Table 1). Plasma concentrations of LDX in 
both portal and systemic circulation peaked by 10 minutes 
postdose (time to maximum plasma concentration [Tmax] 
0.17 hours). d-Amphetamine was measurable in both portal 
and systemic plasma shortly after dosing, suggesting rapid 
conversion of LDX to d-amphetamine after absorption, 
and plasma d-amphetamine in both portal and systemic 
circulation peaked between one and two hours postdosing. 
LDX and d-amphetamine had similar area under the plasma 
  concentration time curve from time 0 hour to last time point 
(AUClast) in portal plasma, but the AUClast of d-amphetamine 
was approximately 3.2-fold higher than the AUClast for LDX 
in systemic plasma, suggesting there is presystemic (ie, 
in portal blood before entry into the systemic circulation) 
  conversion of LDX to d-amphetamine (Table 1). In addition, 
portal blood levels of LDX were approximately 10-fold 
higher than systemic levels (AUClast for LDX in systemic and Neuropsychiatric Disease and Treatment 2010:6 321
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portal blood was 158.0 and 1501.1 ng•h/mL, respectively, 
Table 1), indicating presystemic conversion of LDX to 
d-amphetamine in the rat model.
Single-pass intestinal perfusion in anesthetized rats
LDX absorption was detected from the duodenum, jejunum, 
and ileum during regional perfusions of isolated intestinal 
segments in rats. LDX and d-amphetamine plasma 
  concentrations rose initially during perfusion of the jejunal 
segments and then remained stable, whereas LDX and 
d-amphetamine plasma concentrations during duodenal and 
ileal perfusion increased steadily throughout the experiments 
(Figure 3). Very little plasma LDX and d-amphetamine was 
seen during perfusion of the colon (Figure 3). In addition, 
plasma d-amphetamine concentrations rose steadily 
  throughout the experiment after perfusion of all segments 
except the colon. Mean (SD) d-amphetamine concentrations 
in plasma were 24.2 (16.4), 19.0 (7.0), and 29.5 (6.0) ng/mL 
at 120 minutes after perfusion of the duodenum, jejunum, and 
ileum, respectively, and 0.9 (1.2) ng/mL in the colon.
Carrier-mediated transport of LDX in noninduced 
and PEPT1-overexpressing Caco-2 cells
Carrier-mediated directional LDX transport was demonstrated 
in Caco-2 cells that endogenously express PEPT1. Approxi-
mately half the LDX and d-amphetamine transported across 
Caco-2 cells was converted to d-amphetamine, presumably by 
endogenous peptidases, so total LDX transport was measured 
by assay of LDX and d-amphetamine in incubates. Total LDX 
was transported across the epithelial layer of Caco-2 cells, 
although the apparent permeability (Papp) rate was low. The 
mean [SD] Papp of total LDX transport in Caco-2 cells (0.67 
[0.17] × 10−6 cm/s) was similar to that seen for cephalexin 
(0.64 [0.08] × 10−6 cm/s). The mean [SD] Papp of total LDX 
decreased (P  0.05) by approximately 50% in the presence 
of Gly-Sar (0.30 [0.04] × 10−6 cm/s), an inhibitor of PEPT1, 
suggesting LDX transport was mediated by PEPT1.
Incubation of Caco-2 cells with Gly-Sar resulted in 
  induction of PEPT1 mRNA and functional activity, as well 
as induction of Gly-Sar-inhibitable total LDX transport. 
  Preliminary experiments found 2.15- and 1.40-fold PEPT1 
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Figure 2 Mean (SD) of systemic (A) and portal (B) plasma concentration versus time for LDX and d-amphetamine in rats.
Abbreviations: LDX, lisdexamfetamine dimesylate; SD, standard deviation.
Table 1 Mean (SD) systemic and portal pharmacokinetic parameters in Sprague–Dawley rats
Systemic Portal
LDX d-Amphetamine LDX d-Amphetamine
Cmax (ng/mL) 178.4 (153.1) 124.5 (26.6) 1759.5 (1075.3) 336.8 (40.0)
Tmax (h) 0.17 (0.0) 1.7 (0.6) 0.17 (0.0) 1.0 (0.0)
AUClast (ng•h/mL) 158.0 (89.4) 511.5 (222.1) 1501.1 (680.6) 1301.5 (414.9)
AUCinf (ng•h/mL) 115.5 (ND) 528.0 (214.8) 1507.0 (686.7) 1315.8 (418.6)
t½ (h) 0.9 (ND) 2.5 (1.3) 1.2 (0.4) 4.4 (0.4)
Abbreviations: LDX, lisdexamfetamine dimesylate; SD, standard deviation; Cmax, maximum plasma concentration;  Tmax, time to maximum plasma concentration; AUClast, area under 
the plasma concentration-time curve from time 0 hour to last time point; AUCinf, area under the plasma concentration-time curve from time 0 hour to infinity; t1/2, half-life.Neuropsychiatric Disease and Treatment 2010:6 322
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mRNA induction after 48 hours of incubation with 10 mM 
Gly-Sar. This induction time was used in all subsequent 
  experiments. Functional induction of PEPT1 by 48-hour 
  incubation in Gly-Sar was demonstrated by an increased 
Papp for cephalexin from 0.81 × 10−6 cm/s to 1.47 × 10−6 cm/s 
(P  0.05). As shown in Figure 4, induction of Caco-2 cells 
with Gly-Sar for 48 hours also resulted in a 1.3-fold 
increased Papp for total LDX from 0.39 × 10−6 cm/s to 
0.51 × 10−6 cm/s, although this increase was not statistically 
  significant. Incubation in the presence of Gly-Sar and LDX 
decreased total LDX transport in these Caco-2 cells by 39% 
(Papp decreased from 0.51 × 10−6 cm/s to 0.31 × 10−6 cm/s, 
P  0.05) (Figure 4).
Inhibition of Gly-Sar transport by LDX in CHO cells
LDX inhibited uptake of radiolabeled Gly-Sar by CHO cells 
stably expressing either human PEPT1 or PEPT2 (dipeptide 
transporters), in a concentration-dependent manner (Figure 5). 
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For PEPT1 uptake inhibition, the maximum efficacy was 63% 
at 10 mM LDX concentration, with an IC50 of approximately 
4 mM. For PEPT2 uptake inhibition, maximum efficacy was 
100% at 10 mM LDX, with an IC50 of 246 µM.
Hydrolysis of LDX
LDX was stable and no d-amphetamine formation was 
measured in all negative controls for tissue and enzyme 
incubations.
LDX stability in rat tissues
LDX was metabolized in rat whole blood and liver tissue. 
There was a rapid decrease in LDX concentrations and a 
corresponding increase in d-amphetamine appearance in 
incubations with liver homogenates and in whole blood. The 
half-life (t½) of disappearance of LDX was 2.5 and 1.0 hours in 
rat liver and whole blood, respectively. In contrast, LDX was 
stable, and the formation of d-amphetamine was negligible in 
incubations with the other rat tissue homogenates investigated 
(upper and lower intestines, pancreas, and plasma). There was 
a slight decline in LDX levels over time, with a corresponding 
slight increase in d-amphetamine in incubations with kidney 
and colon homogenates.
LDX stability in human tissues
LDX was metabolized in human whole blood and kidney 
homogenate and to a lesser extent in liver homogenate. 
LDX levels rapidly decreased over time with concomi-
tant formation of d-amphetamine (Figure 6) in whole 
blood and kidney homogenates. The t½ of disappearance 
of LDX averaged 1.6, 2.3, and 9.7 hours for whole blood, 
  kidney homogenate, and liver homogenate, respectively. 
LDX concentrations were stable and d-amphetamine 
  formation was negligible in incubations with homogenates 
of the upper and lower intestines, pancreas, and plasma 
from human donors (data not shown). In incubations of 
colon homogenates, there was intersubject variability. 
In the incubation of colon tissue from donor 1, LDX 
  concentrations decreased (t1/2 was approximately 3.7 hours), 
whereas in the incubation of colon tissue from donor 2, 
LDX concentrations were stable. Colon tissue from a third 
donor was incubated and LDX concentrations were stable 
(Figure 6).
In complementary experiments, LDX was stable in 
incubations over 30 minutes, with human liver microsomes 
and in incubations over four hours with freshly isolated rat 
and human hepatocytes. No d-amphetamine formation was 
detected in these incubations.
LDX stability in human blood cell fractions
LDX was metabolized by human RBCs. In incubations 
with RBCs, LDX was converted rapidly and the formation 
of d-amphetamine increased concurrently (Figure 7). The 
t½ of disappearance of LDX in incubations with RBCs 
  averaged 1.0 hours (0.87 and 1.10 hours for RBC fractions 
from two human donors). LDX concentrations were stable 
and d-amphetamine formation was negligible in incubations 
with PBMCs, PMNs, and platelets (Figure 7).
The concentration of LDX decreased over time, and 
d-amphetamine levels increased in the incubations with 
reconstituted RBC fractions at various hematocrits, with 
the highest hematocrit (90%) showing a conversion rate 
most like that of fresh whole RBCs (Figures 7 and 8). The 
rate of hydrolysis of LDX tended to decrease as the RBC 
fractions were diluted, although there was still substantial 
conversion at the lowest concentrations of RBC fractions 
1 10 100 1000 10000 100000 1 10 100 1000 10000 100000
0
25
50
75
100
125
0
25
50
75
100
125
LDX concentration (µM) LDX concentration (µM)
R
e
l
a
t
i
v
e
 
a
c
t
i
v
i
t
y
 
(
%
)
R
e
l
a
t
i
v
e
 
a
c
t
i
v
i
t
y
 
(
%
)
A B
PEPT1 uptake PEPT2 uptake
Figure 5 Uptake of radiolabeled Gly-Sar in the presence of increasing concentration of LDX by CHO cells expressing PEPT1 (A) or PEPT2 (B).
Abbreviations: LDX, lisdexamfetamine dimesylate; Gly-Sar, glycylsarcosine; CHO, Chinese hamster ovary; PEPT, peptide transporter.Neuropsychiatric Disease and Treatment 2010:6 324
Pennick Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
(10% and 25% of normal hematocrit). Lysis of RBCs did 
not affect the rate of LDX conversion. The addition of 
EDTA to reconstituted RBCs did not inhibit the rate of 
LDX hydrolysis.
LDX stability in in vitro assays
LDX was stable and d-amphetamine formation was negligi-
ble in incubations with dipeptidyl/peptidase IV , cathepsin G, 
and elastase. LDX was also stable in SGF and SIF up to 
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Figure 6 LDX remaining (percentage of initial concentration) after incubation with human tissue homogenates from donors.
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60 minutes. LDX was stable in incubations with trypsin, even 
when very high trypsin concentrations were used.
Discussion
The intact prodrug, LDX, was readily absorbed from the GI 
tract after oral administration, with relatively high levels of 
LDX detected in the portal blood of rats. When LDX was 
perfused into isolated segments of rat duodenum, jejunum, 
and ileum, it was absorbed into the systemic circulation; 
  however, LDX was not absorbed during perfusion into 
colonic segments. These findings indicate that absorption 
of LDX occurs via carrier-mediated transport in the small 
intestines and are consistent with the physicochemical 
  properties of LDX (ie, high aqueous solubility of greater than 
0.85 g/mL within the physiologically relevant pH range of 
1 to 812 and low lipophilicity [logP −1.75, unpublished data]), 
which would predict poor passive diffusion across biologic 
membranes. The prodrug LDX can be considered to be a 
peptidomimetic, in which the naturally occurring amino acid, 
l-lysine, is covalently linked to d-amphetamine. Therefore, 
it is likely that LDX will be a substrate for peptide transport 
proteins such as PEPT1 and PEPT2. Because PEPT1 is highly 
expressed in the small intestines, but not in the colon of adult 
rats,13 the profile of LDX absorption observed in our studies 
is consistent with PEPT1-mediated transport.
To further investigate the involvement of the PEPT1 
transporter in absorption of LDX, permeability experiments 
in Caco-2 cells were conducted, as PEPT1 has been shown to 
be expressed in this cell line.14–16 LDX flux across Caco-2 cells 
was similar in magnitude to the measured flux of cephalexin, 
a known substrate for the PEPT1 transporter15,17,18 and was 
partially inhibited by Gly-Sar, an established competitive 
substrate for PEPT1. Additionally, LDX transport in 
Caco-2 cells correlated well with the expression level of 
PEPT1, in that higher transport was demonstrated in cells 
in which PEPT1 had been induced (both in terms of mRNA 
and functionality). The affinity of LDX for human PEPT1 
and PEPT2 transporters was confirmed in transfected CHO 
cells. Based on inhibition of Gly-Sar uptake, LDX had 
a low affinity for PEPT1 (∼4 mM) and a relatively high 
affinity for PEPT2 (∼200 µM), values that reflected the low 
  affinity/high capacity and high affinity/low capacity of these 
two transporters, respectively. LDX is, therefore, a potential 
substrate for both transporters; however, the localization of 
PEPT1 in the small intestines suggests that LDX absorption 
is likely to be mediated by PEPT1 rather than PEPT2. Of 
course, the involvement of other peptide and amino acid 
  transporters in the absorption of LDX in man cannot be ruled 
out. PEPT1 transport is characterized as a high-capacity 
uptake system for amino acids and drug ligands that mediates 
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Figure 8 LDX remaining (percentage of initial concentration) after incubation with varying hematocrits of RBCs from a male and female donor.
Abbreviations: LDX, lisdexamfetamine dimesylate; RBC, red blood cells; t1/2, half-life.Neuropsychiatric Disease and Treatment 2010:6 326
Pennick Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
fast and efficient intestinal uptake, even in settings of 
impaired mucosal function.19 These findings are consistent 
with the apparent lack of effect of concomitant food intake 
on absorption of PEPT1 substrates such as cephalexin20 and, 
similarly, with data demonstrating that food does not impair 
LDX bioavailability.21
d-Amphetamine was detected in portal blood shortly 
after oral dosing, suggesting rapid metabolism of LDX 
to d-amphetamine, either during or immediately after 
  absorption. Previous evidence suggested that this enzymatic 
conversion likely occurs by first-pass intestinal and/or hepatic 
metabolism.22 The current findings suggest that LDX is 
  primarily absorbed intact in the small intestines into the 
portal circulation and that enzymatic hydrolysis of LDX 
occurs primarily in the blood.
Although these rat studies were not intended to establish 
a detailed pharmacokinetic profile in this setting, the 
results are consistent with previous LDX studies in healthy 
human volunteers. After intravenous administration, the 
  pharmacokinetic profile of d-amphetamine from intact LDX 
(50 mg) was delayed compared with injected d-amphetamine 
(20 mg).23 However, mean (SD) total exposure (AUC0–24 hours) 
to d-amphetamine from LDX was 562.7 (115.5) versus 681.4 
(96.69) for injected d-amphetamine.23 Interestingly, while the 
pharmacokinetic profiles of intact LDX following oral and 
intranasal administration differ in that plasma LDX reaches 
an earlier higher peak after intranasal versus oral LDX, the 
pharmacokinetic profiles of d-amphetamine from LDX after 
intranasal and oral administration are virtually identical.24 
Pharmacokinetic parameters of d-amphetamine from LDX 
were dose-proportional over a wide range of oral doses, 
ranging from therapeutic doses to doses three to eight times 
higher than therapeutic range.3 The consistent findings that 
administration of LDX results in an extended-release profile 
of d-amphetamine across multiple routes of administration 
and an extended dose range provides substantial support 
that systemic delivery of d-amphetamine is dependent on 
the rate-limiting conversion of LDX.
LDX was not metabolized in vitro by SGF, SIF, or 
trypsin, supporting our view that any conversion of LDX 
to d-amphetamine in the GI tract in vivo is likely to be 
minimal. Taken together, these findings are consistent with 
a model of absorption of predominantly intact LDX with 
subsequent enzymatic conversion to active d-amphetamine 
and l-lysine.
LDX was metabolized to d-amphetamine in rat and 
human whole blood but not in plasma. Although metabolism 
was also observed in rat and human liver homogenates and in 
human kidney homogenate, it is possible that the conversion 
of LDX in these tissues was related to residual blood that was 
not removed when these tissues, which have very rich blood 
supply, were excised from the animal or human donor. The 
lack of conversion of LDX in assays with liver microsomes 
and assays with freshly isolated hepatocytes provides further 
support that RBCs in the portal circulation, rather than liver 
tissue, are responsible for the presystemic conversion of 
LDX to d-amphetamine.
LDX was metabolized to d-amphetamine by human 
RBCs but not by other blood fractions, such as white blood 
cells or platelets. Moreover, RBCs had a very high capacity 
for the metabolism of LDX. The rate of metabolism was not 
substantially reduced until concentrations of RBCs were 
reduced to 10% of normal hematocrit. Lysis of the RBCs 
also had little impact on the rate of metabolism of LDX, and 
nor did EDTA (a calcium chelator that inhibits the activity 
of calcium-dependent enzymes).
In conclusion, LDX is absorbed as the intact prodrug 
and converted to inactive l-lysine and active d-amphetamine 
primarily in the blood by RBCs. The absorption of LDX 
likely occurs via a high-capacity carrier-mediated transport 
system involving PEPT1 in the small intestine, although 
the involvement of other peptide and amino acid trans-
porters cannot be ruled out. The subsequent metabolism 
of LDX to d-amphetamine by RBCs also appears to be 
via a high-capacity system. Thus, saturation of enzymatic 
  conversion of LDX in the blood is unlikely to occur at 
therapeutic doses. The dual findings of high-capacity 
absorption and enzymatic conversion may contribute to the 
consistent and reproducible pharmacokinetic profile of LDX 
in humans.2,3 That LDX is subject to enzymatic hydrolysis 
after absorption, but is not subject to variations in absorption 
related to changes in factors such as gastric pH and variations 
in normal GI transit time12,21,25 may result in a consistent 
rate of hydrolysis and delivery of active d-amphetamine, 
compared with formulation-based delivery systems of 
d-amphetamine. Thus, the biotransformation process, and 
not the dissolution of intact LDX, appears to control the rate 
of delivery of active d-amphetamine.
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